2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

By Rishika Sadam and Kashish Tandon Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg ...

The company's worst days might be behind it.

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...